Research and regulatory reference
GHK-Cu (Topical)
A source-linked reference on the identity and evidence context of GHK-Cu (Topical). Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Identity
GHK-Cu is the copper complex of glycyl-histidyl-lysine. A topical review distinguishes GHK-Cu from GHK and other modified GHK derivatives, while a name alone does not verify a finished product’s formulation, concentration or purity.
Sources: PubMed, National Library of Medicine
A named substance and a finished product are different claims. The name does not verify formulation, concentration, purity or equivalence to material used in a study.
Topical research context
A 2025 review specifically examined topical GHK and its derivatives. It reports that GHK-Cu is used in cosmetic products but that published information on skin permeability and effectiveness is insufficient, with a surprising absence of clinical studies using GHK-Cu.
Sources: PubMed, National Library of Medicine
This is topical research context, not evidence that a particular topical product produces a therapeutic effect.
Route-specific regulatory context
FDA’s compounding-risk table names GHK-Cu only for injectable routes of administration. That entry should not be read as a finding about topical GHK-Cu, and it does not establish a clinical outcome or product-quality result for any item.
Sources: U.S. Food and Drug Administration
The appropriate conclusion is limited to the cited topical review and the FDA’s stated injectable scope, not to untested products or uses.
Published sources
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective
PubMed, National Library of Medicine. Published 2025; accessed 6 September 2026.
Supports: Topical GHK-Cu context and the review’s conclusion that clinical evidence for GHK-Cu is insufficient.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food and Drug Administration. Current FDA compounding-risk page; accessed 6 September 2026.
Supports: FDA’s molecule-specific row for GHK-Cu is expressly scoped to injectable routes of administration.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.